Search

Your search keyword '"Pitchiaya, Sethuramasundaram"' showing total 5 results
Start Over Author "Pitchiaya, Sethuramasundaram" Database OAIster
5 results on '"Pitchiaya, Sethuramasundaram"'

1. Analysis of the androgen receptor-regulated lncRNA landscape identifies a role for ARLNC1 in prostate cancer progression.

Author

Zhang, Yajia, Zhang, Yajia, Pitchiaya, Sethuramasundaram, Cieślik, Marcin, Niknafs, Yashar S, Tien, Jean C-Y, Hosono, Yasuyuki, Iyer, Matthew K, Yazdani, Sahr, Subramaniam, Shruthi, Shukla, Sudhanshu K, Jiang, Xia, Wang, Lisha, Liu, Tzu-Ying, Uhl, Michael, Gawronski, Alexander R, Qiao, Yuanyuan, Xiao, Lanbo, Dhanasekaran, Saravana M, Juckette, Kristin M, Kunju, Lakshmi P, Cao, Xuhong, Patel, Utsav, Batish, Mona, Shukla, Girish C, Paulsen, Michelle T, Ljungman, Mats, Jiang, Hui, Mehra, Rohit, Backofen, Rolf, Sahinalp, Cenk S, Freier, Susan M, Watt, Andrew T, Guo, Shuling, Wei, John T, Feng, Felix Y, Malik, Rohit, Chinnaiyan, Arul M, Zhang, Yajia, Zhang, Yajia, Pitchiaya, Sethuramasundaram, Cieślik, Marcin, Niknafs, Yashar S, Tien, Jean C-Y, Hosono, Yasuyuki, Iyer, Matthew K, Yazdani, Sahr, Subramaniam, Shruthi, Shukla, Sudhanshu K, Jiang, Xia, Wang, Lisha, Liu, Tzu-Ying, Uhl, Michael, Gawronski, Alexander R, Qiao, Yuanyuan, Xiao, Lanbo, Dhanasekaran, Saravana M, Juckette, Kristin M, Kunju, Lakshmi P, Cao, Xuhong, Patel, Utsav, Batish, Mona, Shukla, Girish C, Paulsen, Michelle T, Ljungman, Mats, Jiang, Hui, Mehra, Rohit, Backofen, Rolf, Sahinalp, Cenk S, Freier, Susan M, Watt, Andrew T, Guo, Shuling, Wei, John T, Feng, Felix Y, Malik, Rohit, and Chinnaiyan, Arul M

Abstract

The androgen receptor (AR) plays a critical role in the development of the normal prostate as well as prostate cancer. Using an integrative transcriptomic analysis of prostate cancer cell lines and tissues, we identified ARLNC1 (AR-regulated long noncoding RNA 1) as an important long noncoding RNA that is strongly associated with AR signaling in prostate cancer progression. Not only was ARLNC1 induced by the AR protein, but ARLNC1 stabilized the AR transcript via RNA-RNA interaction. ARLNC1 knockdown suppressed AR expression, global AR signaling and prostate cancer growth in vitro and in vivo. Taken together, these data support a role for ARLNC1 in maintaining a positive feedback loop that potentiates AR signaling during prostate cancer progression and identify ARLNC1 as a novel therapeutic target.

Published
2018

2. Analysis of the androgen receptor-regulated lncRNA landscape identifies a role for ARLNC1 in prostate cancer progression.

Author

Zhang, Yajia, Zhang, Yajia, Pitchiaya, Sethuramasundaram, Cieślik, Marcin, Niknafs, Yashar S, Tien, Jean C-Y, Hosono, Yasuyuki, Iyer, Matthew K, Yazdani, Sahr, Subramaniam, Shruthi, Shukla, Sudhanshu K, Jiang, Xia, Wang, Lisha, Liu, Tzu-Ying, Uhl, Michael, Gawronski, Alexander R, Qiao, Yuanyuan, Xiao, Lanbo, Dhanasekaran, Saravana M, Juckette, Kristin M, Kunju, Lakshmi P, Cao, Xuhong, Patel, Utsav, Batish, Mona, Shukla, Girish C, Paulsen, Michelle T, Ljungman, Mats, Jiang, Hui, Mehra, Rohit, Backofen, Rolf, Sahinalp, Cenk S, Freier, Susan M, Watt, Andrew T, Guo, Shuling, Wei, John T, Feng, Felix Y, Malik, Rohit, Chinnaiyan, Arul M, Zhang, Yajia, Zhang, Yajia, Pitchiaya, Sethuramasundaram, Cieślik, Marcin, Niknafs, Yashar S, Tien, Jean C-Y, Hosono, Yasuyuki, Iyer, Matthew K, Yazdani, Sahr, Subramaniam, Shruthi, Shukla, Sudhanshu K, Jiang, Xia, Wang, Lisha, Liu, Tzu-Ying, Uhl, Michael, Gawronski, Alexander R, Qiao, Yuanyuan, Xiao, Lanbo, Dhanasekaran, Saravana M, Juckette, Kristin M, Kunju, Lakshmi P, Cao, Xuhong, Patel, Utsav, Batish, Mona, Shukla, Girish C, Paulsen, Michelle T, Ljungman, Mats, Jiang, Hui, Mehra, Rohit, Backofen, Rolf, Sahinalp, Cenk S, Freier, Susan M, Watt, Andrew T, Guo, Shuling, Wei, John T, Feng, Felix Y, Malik, Rohit, and Chinnaiyan, Arul M

Abstract

The androgen receptor (AR) plays a critical role in the development of the normal prostate as well as prostate cancer. Using an integrative transcriptomic analysis of prostate cancer cell lines and tissues, we identified ARLNC1 (AR-regulated long noncoding RNA 1) as an important long noncoding RNA that is strongly associated with AR signaling in prostate cancer progression. Not only was ARLNC1 induced by the AR protein, but ARLNC1 stabilized the AR transcript via RNA-RNA interaction. ARLNC1 knockdown suppressed AR expression, global AR signaling and prostate cancer growth in vitro and in vivo. Taken together, these data support a role for ARLNC1 in maintaining a positive feedback loop that potentiates AR signaling during prostate cancer progression and identify ARLNC1 as a novel therapeutic target.

Published
2018

3. The lncRNA landscape of breast cancer reveals a role for DSCAM-AS1 in breast cancer progression.

Author

Niknafs, Yashar S, Niknafs, Yashar S, Han, Sumin, Ma, Teng, Speers, Corey, Zhang, Chao, Wilder-Romans, Kari, Iyer, Matthew K, Pitchiaya, Sethuramasundaram, Malik, Rohit, Hosono, Yasuyuki, Prensner, John R, Poliakov, Anton, Singhal, Udit, Xiao, Lanbo, Kregel, Steven, Siebenaler, Ronald F, Zhao, Shuang G, Uhl, Michael, Gawronski, Alexander, Hayes, Daniel F, Pierce, Lori J, Cao, Xuhong, Collins, Colin, Backofen, Rolf, Sahinalp, Cenk S, Rae, James M, Chinnaiyan, Arul M, Feng, Felix Y, Niknafs, Yashar S, Niknafs, Yashar S, Han, Sumin, Ma, Teng, Speers, Corey, Zhang, Chao, Wilder-Romans, Kari, Iyer, Matthew K, Pitchiaya, Sethuramasundaram, Malik, Rohit, Hosono, Yasuyuki, Prensner, John R, Poliakov, Anton, Singhal, Udit, Xiao, Lanbo, Kregel, Steven, Siebenaler, Ronald F, Zhao, Shuang G, Uhl, Michael, Gawronski, Alexander, Hayes, Daniel F, Pierce, Lori J, Cao, Xuhong, Collins, Colin, Backofen, Rolf, Sahinalp, Cenk S, Rae, James M, Chinnaiyan, Arul M, and Feng, Felix Y

Abstract

Molecular classification of cancers into subtypes has resulted in an advance in our understanding of tumour biology and treatment response across multiple tumour types. However, to date, cancer profiling has largely focused on protein-coding genes, which comprise <1% of the genome. Here we leverage a compendium of 58,648 long noncoding RNAs (lncRNAs) to subtype 947 breast cancer samples. We show that lncRNA-based profiling categorizes breast tumours by their known molecular subtypes in breast cancer. We identify a cohort of breast cancer-associated and oestrogen-regulated lncRNAs, and investigate the role of the top prioritized oestrogen receptor (ER)-regulated lncRNA, DSCAM-AS1. We demonstrate that DSCAM-AS1 mediates tumour progression and tamoxifen resistance and identify hnRNPL as an interacting protein involved in the mechanism of DSCAM-AS1 action. By highlighting the role of DSCAM-AS1 in breast cancer biology and treatment resistance, this study provides insight into the potential clinical implications of lncRNAs in breast cancer.

Published
2016

4. The lncRNA landscape of breast cancer reveals a role for DSCAM-AS1 in breast cancer progression.

Author

Niknafs, Yashar S, Niknafs, Yashar S, Han, Sumin, Ma, Teng, Speers, Corey, Zhang, Chao, Wilder-Romans, Kari, Iyer, Matthew K, Pitchiaya, Sethuramasundaram, Malik, Rohit, Hosono, Yasuyuki, Prensner, John R, Poliakov, Anton, Singhal, Udit, Xiao, Lanbo, Kregel, Steven, Siebenaler, Ronald F, Zhao, Shuang G, Uhl, Michael, Gawronski, Alexander, Hayes, Daniel F, Pierce, Lori J, Cao, Xuhong, Collins, Colin, Backofen, Rolf, Sahinalp, Cenk S, Rae, James M, Chinnaiyan, Arul M, Feng, Felix Y, Niknafs, Yashar S, Niknafs, Yashar S, Han, Sumin, Ma, Teng, Speers, Corey, Zhang, Chao, Wilder-Romans, Kari, Iyer, Matthew K, Pitchiaya, Sethuramasundaram, Malik, Rohit, Hosono, Yasuyuki, Prensner, John R, Poliakov, Anton, Singhal, Udit, Xiao, Lanbo, Kregel, Steven, Siebenaler, Ronald F, Zhao, Shuang G, Uhl, Michael, Gawronski, Alexander, Hayes, Daniel F, Pierce, Lori J, Cao, Xuhong, Collins, Colin, Backofen, Rolf, Sahinalp, Cenk S, Rae, James M, Chinnaiyan, Arul M, and Feng, Felix Y

Abstract

Molecular classification of cancers into subtypes has resulted in an advance in our understanding of tumour biology and treatment response across multiple tumour types. However, to date, cancer profiling has largely focused on protein-coding genes, which comprise <1% of the genome. Here we leverage a compendium of 58,648 long noncoding RNAs (lncRNAs) to subtype 947 breast cancer samples. We show that lncRNA-based profiling categorizes breast tumours by their known molecular subtypes in breast cancer. We identify a cohort of breast cancer-associated and oestrogen-regulated lncRNAs, and investigate the role of the top prioritized oestrogen receptor (ER)-regulated lncRNA, DSCAM-AS1. We demonstrate that DSCAM-AS1 mediates tumour progression and tamoxifen resistance and identify hnRNPL as an interacting protein involved in the mechanism of DSCAM-AS1 action. By highlighting the role of DSCAM-AS1 in breast cancer biology and treatment resistance, this study provides insight into the potential clinical implications of lncRNAs in breast cancer.

Published
2016

5. KRAS Engages AGO2 to Enhance Cellular Transformation.

Author

Shankar, Sunita, Shankar, Sunita, Pitchiaya, Sethuramasundaram, Malik, Rohit, Kothari, Vishal, Hosono, Yasuyuki, Yocum, Anastasia K, Gundlapalli, Harika, White, Yasmine, Firestone, Ari, Cao, Xuhong, Dhanasekaran, Saravana M, Stuckey, Jeanne A, Bollag, Gideon, Shannon, Kevin, Walter, Nils G, Kumar-Sinha, Chandan, Chinnaiyan, Arul M, Shankar, Sunita, Shankar, Sunita, Pitchiaya, Sethuramasundaram, Malik, Rohit, Kothari, Vishal, Hosono, Yasuyuki, Yocum, Anastasia K, Gundlapalli, Harika, White, Yasmine, Firestone, Ari, Cao, Xuhong, Dhanasekaran, Saravana M, Stuckey, Jeanne A, Bollag, Gideon, Shannon, Kevin, Walter, Nils G, Kumar-Sinha, Chandan, and Chinnaiyan, Arul M

Abstract

Oncogenic mutations in RAS provide a compelling yet intractable therapeutic target. Using co-immunoprecipitation mass spectrometry, we uncovered an interaction between RAS and Argonaute 2 (AGO2). Endogenously, RAS and AGO2 co-sediment and co-localize in the endoplasmic reticulum. The AGO2 N-terminal domain directly binds the Switch II region of KRAS, agnostic of nucleotide (GDP/GTP) binding. Functionally, AGO2 knockdown attenuates cell proliferation in mutant KRAS-dependent cells and AGO2 overexpression enhances KRAS(G12V)-mediated transformation. Using AGO2-/- cells, we demonstrate that the RAS-AGO2 interaction is required for maximal mutant KRAS expression and cellular transformation. Mechanistically, oncogenic KRAS attenuates AGO2-mediated gene silencing. Overall, the functional interaction with AGO2 extends KRAS function beyond its canonical role in signaling.

Published
2016

Catalog

Books, media, physical & digital resources
See catalog results